The immunological and clinical effects of mutated ras peptide vaccine in combination with IL-2, GM-CSF, or both in patients with solid tumors

Table 1 Ras peptides used for vaccination

Ras peptides	Amino acid sequence	Vaccinated patients by arm
	5 6 7 8 9 10 11 12 13 14 15 16 17
ras 5-17	Lys- Leu-Val- Val- Val- Gly- Ala- Gly- Gly- Val- Gly- Lys- Ser	Nome
(wild type)
ras 5-17	Lys- Leu-Val- Val- Val- Gly- Ala- Asp- Gly- Val- Gly- Lys- Ser	A: 1-4, 9-12, 14, 16
(Gly→Asp)		B: 3-6, 8-10, 14-16
		C: 1-5, 7, 9-11, 13-19
ras 5-17	Lys- Leu-Val- Val- Val- Gly- Ala- Val- Gly- Val- Gly- Lys- Ser	A: 5, 6, 15
(Gly→Val)		B: 1, 7, 11, 12, 17, 18
		C: 6, 12
ras 5-17	Lys- Leu-Val- Val- Val- Gly- Ala- Cys- Gly- Val- Gly- Lys- Ser	A: 7, 8, 13
(Gly→Cys)		B: 2, 13
		C: 8

The peptides used in the study were 13-mer peptides (residues 5-17) corresponding to the tumor Ras mutations. Corresponding mutant part of the peptide is bolded.

ISSN: 1479-5876